Symbol: CXG.A-TSX Venture
Shares Outstanding: 18,674,810
MONTREAL, Aug. 22 /CNW Telbec/ - Clemex Technologies Inc.
(TSX Venture: CXG.a) announces today that it has recently sold three PS3
instruments for Particle Size and Shape analysis to clients in the
pharmaceutical sector. The instruments were sold for a total of $306,475 to
PPD of Middleton WI, USA, Intranasal Therapeutics inc R&D Laboratories of
Lexington KY, USA and to Draxis Pharma of Montreal QC, Canada. Two of these
clients will use their instrument primarily for the testing and development of
nasal sprayed drugs and other fine powders while the third one will be using
it primarily for the measurement of fine micronised particles. The three
instruments are Research type, meaning that they include fully automated high
The President and CEO, Clément Forget declared the following: "We are
quite pleased with these three orders received in a six week period. We have
put a lot of efforts in the last year in the marketing of this new product and
it now begins to payoff. We have several other prospects in line to purchase
these systems and we will pursue our marketing and education efforts in order
to close these sales in the next quarters." He continued;, "Clemex has a
substantial technological lead in automated Particle Size analysis by
microscopy and an excellent reputation amongst instrument suppliers in the
industry and we intend to capitalize on this as much as we can.
About Clemex Technologies, Inc.
Clemex Technologies Inc. develops, manufactures and markets image
analysis systems and software used by quality control and research microscopy
laboratories. Clemex customer base spans over many countries in America,
Europe, Asia and encompasses major Research and Development Centers,
prestigious Universities and large manufacturing industries in various fields
including automotive, aerospace, raw materials manufacturing, pharmaceuticals,
mining and other sectors.
PPD is a leading global contract research organization (CRO) providing
discovery, development and post-approval services as well as compound
partnering programs. PPD clients and partners include pharmaceutical,
biotechnology, medical device, academic and government organizations. With
offices in 28 countries and more than 9,700 professionals worldwide, PPD
applies innovative technologies, therapeutic expertise and a commitment to
quality to help its clients and partners maximize returns on their R&D
investments and accelerate the delivery of safe and effective therapeutics to
About Intranasal Therapeutics Inc.
Intranasal Therapeutics, Inc. (ITI) is a specialty pharmaceutical company
focused on developing innovative nasally delivered pharmaceutical products,
with a particular focus on drugs treating pain and disorders related to the
central nervous system for which there is proven, unsatisfied consumer need.
Their market-driven strategy is designed to capitalize on their unique
expertise and proprietary technology to develop an array of promising new drug
therapies, from product concept to commercialization.
About Draxis Pharma.
Draxis Pharma is a division of Draxis Specialty Pharmaceuticals Inc., a
wholly owned subsidiary of Draxis Health Inc. is a manufacturer of outsourced
pharmaceutical products in a broad range of dosage forms. Our strategy for
success is based on outstanding quality, international regulatory compliance,
superior technology transfer capabilities and consistent on-time performance.
Products manufactured at Draxis Pharma are sold in over 100 countries and
include the following dosage forms: sterile products, non-sterile products and
radiopharmaceuticals. Sterile products include liquid and freeze-dried
(lyophilized) injectables, sterile ointments and sterile creams.
Specialty non-sterile products are produced as tablets, ointments,
liquids and creams. Proprietary radiopharmaceuticals are used for both
therapeutic and diagnostic molecular imaging applications. Pharmaceutical
contract manufacturing services are provided through the DRAXIS Pharma
division and radiopharmaceuticals are developed, produced and sold through the
DRAXIMAGE division. DRAXIS Health employs approximately 500 staff in its
The CDNX has not reviewed and does not accept responsibility for the
adequacy and accuracy of this news release.
For further information:
For further information: Clément Forget, CLEMEX TECHNOLOGIES INC, (450)